Before even reading the paper, let me tell you how to critically appraise it [Thread]
We won't know if we are merely delaying inevitable metastatic recurrence vs. actually curing people
Targeted TKIs don't do well in the adjuvant setting at increasing cure rates
It better NOT BE gefitinib.
If you compare adjuvant osi to gefitinib at recurrence you are running a straw man trial.
The same PI who gives Osi frontline, can't accept gefitinib to control arm
Make sure second line therapy is also appropriate.
When the control arm progresses they will get gefitinib and
Second line therapy will be beneath global best care.
We have to be vigilant
If this happens, the trial should go in the dustbin w other failed adj studies